Photo taken from: Hagop Kantarjian/X
Feb 18, 2024, 15:51
Hagop Kantarjian: In this Ph1b trial, single agent SQ blinatumomab resulted in a high MRD-negative complete remission rate
Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared on X:
“In this Ph1b trial, single agent SQ blinatumomab resulted in a high MRD-negative complete remission rate & an acceptable safety profile in heavily pretreated adults w/ R/R B-ALL
Elias Jabbour of MD Anderson Cancer Center”
Read further.
Source: Hagop Kantarjian/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 19, 2024, 07:51
Dec 19, 2024, 07:45
Dec 19, 2024, 07:38
Dec 19, 2024, 07:27
Dec 19, 2024, 07:24
Dec 19, 2024, 07:21
Dec 19, 2024, 07:20
Dec 19, 2024, 07:17